Epigenetic Therapies for Osteoarthritis

Area of Science:

• Biomedical Science
• Molecular Biology
• Rheumatology

Background:

• Osteoarthritis (OA) is a prevalent age-associated joint disease causing chronic pain due to cartilage degradation, synovial inflammation, and subchondral bone changes.
• Current treatments for OA primarily manage symptoms, as no FDA-approved disease-modifying drugs are available.
• Emerging research highlights epigenetic dysregulation as a critical factor in OA pathogenesis.

Purpose of the Study:

• This review focuses on epigenetic regulators implicated in OA.
• It examines their individual roles, potential crosstalk, and therapeutic implications.
• The review also discusses pharmacological strategies for modulating epigenetic activity in OA.

Main Methods:

• Literature review of recent evidence on epigenetic dysregulation in OA.
• Analysis of the roles of specific epigenetic regulators in OA pathogenesis.
• Discussion of pharmacological agents targeting epigenetic pathways.

Main Results:

• Epigenetic dysregulation affects multiple molecular pathways crucial to OA.
• Specific epigenetic regulators have been identified as key players in OA development.
• Crosstalk between these regulators may contribute to disease progression.

Conclusions:

• Epigenetic mechanisms represent a promising therapeutic axis for OA.
• Targeting epigenetic regulators offers a strategy to potentially modify OA disease progression.
• Further research into epigenome-based therapeutics is warranted to address challenges and explore advantages.